Comparison of the Result of Radiation Alone and Radiation with Daily Low Dose Cisplatin in Management of Locally Advanced Cervical Cancer.
- Author:
Hun Jung KIM
1
;
Woo Chul KIM
;
Mee Jo LEE
;
Chul Su KIM
;
Eun Seop SONG
;
John J K LOH
Author Information
1. Departments of Radiation Oncology, Inha University Medical College, Inchon, Korea. hunjung@inha.com
- Publication Type:Original Article
- Keywords:
Cervix cancer;
Radiation therapy;
Cisplatin
- MeSH:
Bone Marrow;
Brachytherapy;
Cervix Uteri;
Cisplatin*;
Classification;
Disease-Free Survival;
Female;
Follow-Up Studies;
Humans;
Incidence;
Leukopenia;
Pelvis;
Retrospective Studies;
Survival Rate;
Uterine Cervical Neoplasms*
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2004;22(3):200-207
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: An analysis was to compare the results of radiation alone with those of radiation with daily low dose cisplatin as a radiation sensitizer in locally advanced cervical cancer. MATERIALS AND METHODS: A retrospective analysis of 59 patients diagnosed with locally advanced uterine cervix cancer between December 1996 and March 2001 was performed. Thirty one patients received radiation alone and 28 patients received daily low dose cisplatin, as a radiation sensitizer, and radiation therapy. The median follow-up period was 34 months, ranging from 2.5 to 73 months. The radiation therapy consisted of 4500 cGy external beam irradiation to the whole pelvis (midline block after 3060 cGy), a 900~1,000 cGy boost to the involved parametrium and high dose-rate intracavitary brachytherapy (a total dose of 3,000~3,500 cGy/500 cGy per fraction to point A, twice per week). In the chemoradiation group, 10 mg of daily intravenous cisplatin was given daily from the 1st day of radiation therapy to the 20th day of radiation therapy. According to the FIGO classification, the patients were subdivided into 51 (86.4%) and 8 (13.6%) stages IIB and stage IIIB, respectively. RESULTS: The overall 5 year survival rate was 65.65% and according to treatment modality were 56.75% and 73.42% in the radiation alone and chemoradiation groups, respectively (p=0.180). The 5 year disease-free survival rates were 49.39% and 63.34% in the radiation alone and chemoradiatoin groups, respectively (p=0.053). The 5 year locoregional control rates were 52.34% and 73.58% in the radiation alone and chemoradiation groups, respectively (p=0.013). The 5 year distant disease-free survival rates were 59.29% and 81.46% in the radiation alone and chemoradiation groups, respectively (p=0.477). Treatment related hematologic toxicity were prominent in the chemoradiation group. Leukopenia (> or =3 grade) occurred in 3.2% and 28.5% of the radiation alone and chemoradiation groups, respectively (p=0.02). There were no statistical differences in the incidences of vesical, rectal and small bowel complications between two groups. CONCLUSION: Radiation therapy with low dose cisplatin did not improve the rates of survival and response rates, but did improve the rate of disease free survival and locoregional control rates in locally advanced cervical cancer. The incidence of bone marrow suppression was higher in the chemoradiation group.
